Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia
Arief S. Gunawan,
Donal P. McLornan,
Bridget Wilkins,
Katherine Waghorn,
Yvette Hoade,
Nicholas C. P. Cross,
Claire N. Harrison
Affiliations
Arief S. Gunawan
Guy’s and St Thomas’ NHS Foundation Trust, London
Donal P. McLornan
Guy’s and St Thomas’ NHS Foundation Trust, London
Bridget Wilkins
Guy’s and St Thomas’ NHS Foundation Trust, London
Katherine Waghorn
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust and Faculty of Medicine, University of Southampton, UK
Yvette Hoade
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust and Faculty of Medicine, University of Southampton, UK
Nicholas C. P. Cross
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust and Faculty of Medicine, University of Southampton, UK
